Arimidex 1 Tablet is used to treat breast cancer in women who have gone through menopause (cessation of menses periods). Breast cancer is a type of cancer that develops in breast cells stimulated by the female sex hormone known as estrogen.
Arimidex 1 Tablet works by blocking the aromatase enzyme, which is involved in producing the estrogen hormone. The cancer cells require estrogen for their growth. Hence, by blocking the aromatase enzyme, Arimidex 1 Tablet prevents the growth of cancer cells. Together, Arimidex 1 Tablet helps prevent or stop the growth of tumours (cancer cells) in other body parts.
Take Arimidex 1 Tablet as prescribed by your doctor. Depending on your medical conditions, you are advised to take Arimidex 1 Tablet for as long as your doctor prescribes it. In some cases, you may experience common side effects such as headache, musculoskeletal (bone, muscle, or joint) pain, hot flashes, nausea, skin rashes, osteoporosis, and weakness. Do not hesitate to talk with your doctor if you persistently experience any of these side effects.
To treat your condition effectually, continue taking Arimidex 1 Tablet for as long as your doctor has prescribed. Do not stop Arimidex 1 Tablet midway. Talk to your doctor before taking Arimidex 1 Tablet if you have allergies, osteoporosis (thinning of bones), bone fractures, high levels of cholesterol, or severe liver or kidney disease. Avoid taking Arimidex 1 Tablet if you are pregnant or breastfeeding. Arimidex 1 Tablet causes weakness and dizziness, so drive only if you are alert. Arimidex 1 Tablet should not be given to children as safety has not been established. Avoid consuming alcohol with Arimidex 1 Tablet as it could lead to increased drowsiness and dizziness. Inform your doctor about your health condition and medications before taking Arimidex 1 Tablet to rule out any side effects.
Read Morep-2058-2018-05-01T08:40:47ZRead moreRead Morep-2059-2018-05-01T08:40:47Zanticipated: 11:00 AMJul 21, 2022
Cautions
If you experience any of the following side effects, stop taking Arimidex 1 Tablet:
If you experience any of the following side effects that are not listed in this medication guide, contact your doctor:
If you experience any side effects that persist or become bothersome, it is advisable to speak with your doctor. He may have prescribed other medications or provide you with a medical history or health condition that may interact with Arimidex 1 Tablet.
Arimidex is a prescription medication that contains an active ingredient called anastrozole. It is used to treat breast cancer in postmenopausal women. It belongs to a class of drugs called aromatase inhibitors.
| Weight | <30 kg | > | |
| Onset of Breast Cancer | 30 to 45 minutes | ||
| Duration of Breast Cancer | 5 to 6 months | 6 to 12 months | 12 to 18 months |
| Estrogen Control | 0 to 2 years | 2 years | 3 years |
| Breast Cancer Risk/Erectile Dysfunction |
The dosage of Arimidex depends on the individual’s condition and the type of cancer.
Most side effects of Arimidex are temporary and usually disappear as the body adjusts to the medication.
Common side effects of Arimidex are hot flashes, mood changes, and vaginal discharge. These side effects are generally mild and short-lived.
Less common side effects include joint pain, breast tenderness, and nausea. Rare side effects of Arimidex include bone loss, breast enlargement, and breast cancer.
Arimidex may interact with other medications and supplements, affecting their effectiveness or altering their dosages.
Do not use Arimidex if you have an allergic reaction to anastrozole, the active ingredient in Arimidex, other aromatase inhibitors, or any of the ingredients listed at the end of this leaflet. If you have any concerns or questions about Arimidex use, talk to your doctor or pharmacist.
Talk to your doctor before using Arimidex if you have any of these conditions:
INDIANAPOLIS, June 11 /PRNewswire-FirstCall/ --The American Cancer Society (ACS) today announced that the U. S. Food and Drug Administration (FDA) has approved an aromatase inhibitor, Arimidex, for treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease. It is also approved for the treatment of hormone receptor-positive disease in postmenopausal women.
"This approval marks the first time the FDA has approved a new form of therapy for hormone receptor-positive disease," said Dr. Steven Nissen, director of the Cancer Prevention Research Center at The University of Texas Health Science Center at Dallas, in a press release.
The drug was first approved in the United States in August 2001. Since then, Arimidex has been available for more than 20 years, with data showing a 10% rise in tumor size in premenopausal women with postmenopausal hormone receptor-positive disease. A Phase 3 trial has shown that Arimidex has a very modest effect on the growth of hormone receptor-positive tumors and that this effect is not associated with an increase in tumor size.
The FDA also approved an Arimidex monotherapy in 2002 for patients who were treated with the aromatase inhibitor, Tamoxifen, or a combination of two or more of the two inhibitors. In a postmarketing safety study of patients who were treated with Arimidex in Japan, the association of Tamoxifen and Arimidex was not observed, but there was a 50% increase in tumor size in both the premenopausal and postmenopausal women, and a 70% increase in tumor size in both the premenopausal and postmenopausal women.
In addition to the Arimidex monotherapy, the FDA also approved the use of an aromatase inhibitor in conjunction with a tamoxifen receptor-positive breast cancer. In a postmarketing safety study, a combination of Arimidex with tamoxifen and tamoxifen was studied, with the results indicating that the combination had no effect on the overall survival of tamoxifen-naïve patients who had previously received either tamoxifen or anastrozole therapy.
"The approval of Arimidex is an important step in the fight against hormone receptor-positive breast cancer. It is now clear that it is a new therapy that offers new hope to patients," said Dr. Steven Nissen, director of the Cancer Prevention Research Center at The University of Texas Health Science Center at Dallas.
"We hope that the approval of Arimidex will serve as a model for other new therapies in breast cancer, as well as for other forms of hormone receptor-positive disease," said Dr. Steven Nissen, director of the Cancer Prevention Research Center at the University of Texas Health Science Center at Dallas.
The ACCC's joint statement was made available to the media and is available at the following link:
http://www.cg.com/news/articles/2015-08-acclast-adults-change-breast-cancer.html
Source:
The Cancer Prevention Research Center is a National Cancer Institute-led academic and research support program funded by the National Institutes of Health. The research center receives funding from the National Institutes of Health (NIH) under awards ranging from $4.5 million to $8 million. The ACCC is a bi-national, nonprofit, research-based non-profit academic research center that works to support the health, educational, social, and educational needs of low- and middle-income countries. The program was established in 1982 to provide medical and financial support to low and middle-income countries, and to provide continuing medical education to low- and middle-income countries. The Cancer Prevention Research Center provides education to both adults and children who are at risk for breast cancer and to physicians and other care providers in high- and middle-income countries.
The ACCC operates primarily in the United States and plays a significant role in the United Kingdom and the Middle East. The National Institutes of Health is the scientific arm of the NIH, with funding from the American College of Physicians and other government and private organizations. The ACCC is part of the National Institutes of Health, a bi-monthly biomedical research organization dedicated to biomedical research, with a primary mission of advancing the health care needs of low and middle-income countries. The ACCC is the only research-based federal government agency that receives funding from the NIH. The National Institutes of Health, also a bi-monthly biomedical research organization, is also part of the NIH.
The Arimidex 1mg Tablet 14s is a vital pharmaceutical product utilized foraddressing particular forms of breast cancer.The tablet comprisesAnastrozole, an active agent that is part of thearomatase inhibitorsdrug category.
The operational mechanism of this medicine involvessuppressing an enzyme referred to as aromatase,that is involved inestrogen synthesis.By obstructingaromatase,a decline in estrogen levels occurs, which is successful indecelerating or haltingthe progression ofestrogen-receptivebreast cancers. In less complex language,is utilized tooffset the impactsof estrogen, significantlyaiding the treatmentplan for specific breast cancers.
Obstructing the function of thearomatase enzymethroughleads to a consequentialreduction in estrogenlevels. Since certainbreast cancersare dependent on estrogen for their development, this decline in estrogen helps tocurtail the advancement of the cancer.
It's vital tocomply with your doctor's guidelineswhen taking this medication. The pill can be ingestedwith or without nourishment, but sticking to a consistent daily routine is advised for best outcomes.
Using this medication may cause a decline in bone mineral density, increasing the vulnerability to fractures.It is crucial tomonitor bone health regularly,especiallyfor postmenopausal women.Proper consumptionof calcium and vitamin D, combined with weight-bearing physical activities, could be suggested.Postmenopausal femalesusingmight experience a higher probability of developingosteoporosis,whichmandates bone density testsand appropriatepreventative actions.
Side effectslinked with its intake might encompass diarrhea, nausea, osteoporosis, headaches, vaginal bleeding or dryness, sensory disturbances, hot flushes, alopecia, bone soreness, andhypercholesterolemia.
If you forget to take a dose, it should be taken as soon as remembered. If the next dose is due soon, ignore the missed one and maintain the regular schedule.Do not take extra doses to compensate.Consult your healthcare professional for strategies to manage forgotten doses efficiently.Finishingthe prescribed course of the medication is vital forachieving the maximum treatment outcomes.
To view the most commonside effectsof this medicine,daily or combined with exercise, the operational mechanism of this medicine potentialmay be utilized, leading toprevention ofestrogen-receptive breast cancers - is used tooffset the effects of estrogen.Adults and adolescents
The active agentmay enhance the absorption of this medication, offering aeffective alternativeto calories-added diets. It's particularly beneficial forpostmenopausalwomen who may beunsuredtobucks diets.
This medication can beaccidentalif not consumed if you miss a dose. Avoidoverdoseor seek medical advice if you noticeaccidental movementinany formof the medication. Do not consume more thanone tablet per dayon a 14-day course of this medication, nor consume more than15 tablets in any 24 hours
Stade de France Pharmacy